Glaukos (GKOS) Projected to Post Earnings on Wednesday

Glaukos (NYSE:GKOS) is anticipated to announce its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect the company to announce earnings of ($0.0964) per share and revenue of $168.04 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, July 29th. The medical instruments supplier reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. The company had revenue of $185.61 million during the quarter, compared to analyst estimates of $150.93 million. Glaukos had a negative net margin of 30.68% and a negative return on equity of 6.37%. The firm’s revenue for the quarter was up 49.6% on a year-over-year basis. During the same quarter last year, the business posted ($0.24) EPS. On average, analysts expect Glaukos to post ($0.32) EPS for the current fiscal year and $0.55 EPS for the next fiscal year.

Glaukos Price Performance

Shares of GKOS stock opened at $173.71 on Wednesday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. The company’s 50-day simple moving average is $171.89 and its two-hundred day simple moving average is $149.12. Glaukos has a one year low of $73.16 and a one year high of $191.62.

Analysts Set New Price Targets

Several research analysts have commented on the company. Stifel Nicolaus raised their price objective on Glaukos from $175.00 to $190.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 target price (up from $165.00) on shares of Glaukos in a research report on Thursday, July 30th. Citigroup upped their target price on Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Glaukos in a report on Thursday, October 15th. Finally, Truist Financial increased their price target on Glaukos from $180.00 to $215.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.43.

Insider Buying and Selling at Glaukos

In other news, CFO Alex Thurman sold 20,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the transaction, the chief financial officer directly owned 43,906 shares in the company, valued at approximately $7,908,787.78. This trade represents a 31.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gilbert Kliman sold 2,500 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total transaction of $475,000.00. Following the transaction, the director owned 37,406 shares in the company, valued at approximately $7,107,140. This represents a 6.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 83,025 shares of company stock worth $14,950,006 over the last quarter. 5.90% of the stock is currently owned by company insiders.

About Glaukos

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.